Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Secondary screening for systemic lupus erythematosus (SLE) based on ANA results.
MnemonicUnique test identifier.
DNA IFA
MethodologyProcess(es) used to perform the test.
Semi-Quantitative Indirect Fluorescent Antibody
PerformedDays of the week the test is performed.
Sun-Sat
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
1-3 days
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect
Serum separator tube.
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
Plasma. Contaminated, hemolyzed, or severely lipemic specimens.
Remarks
Stability
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
Less than 1:10
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
Positivity for anti-double stranded DNA (anti-dsDNA) IgG antibody is a diagnostic criterion of systemic lupus erythematosus (SLE). The presence of the anti-dsDNA IgG antibody is identified by IFA titer (Crithidia luciliae indirect fluorescent test [CLIFT]). CLIFT is highly specific for SLE with a sensitivity of 50-60 percent.
Some patients with early or inactive SLE may be positive for anti-dsDNA IgG by ELISA but negative by CLIFT. If the CLIFT result is negative but the patient has a positive ELISA and clinical suspicion remains, consider antinuclear antibody (ANA) testing by IFA. Additional information and recommendations for testing may be found at https://www.arupconsult.com/Topics/AutoimmuneDz/ConnectiveTissueDz/index.html.
Compliance Category
FDA
NoteAdditional information related to the test.
Double Stranded DNA (dsDNA) antibodies (1:10 or greater) are found in 50-60 percent of systemic lupus erythematosus (SLE), 20-30 percent in Sjögren syndrome, 20-25 percent in mixed connective tissue disease (MCTD), and less than 5 percent in progressive systemic sclerosis (PSS). High titers of antibody to native (double stranded) DNA are specific for SLE.
Hotline History
N/A
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
anti-DNA
Antibody to ds-DNA
Crithidia luciliae indirect fluorescent test (CLIFT)
Double stranded DNA antibody
Native double-stranded DNA antibody
Double-Stranded DNA (dsDNA) Antibody, IgG by IFA (using Crithidia luciliae)